Pictet Asset Management
VRDN icon

Pictet Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Pictet Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
11,225
-302,806
-96% -$4.88M ﹤0.01% 1981
2026
Q1 		$6.14M Sell
314,031
-608,736
-66% -$18.1M 0.01% 751
2025
Q4 		$28.7M Sell
922,767
-126,618
-12% -$3.47M 0.03% 437
2025
Q3 		$22.6M Sell
1,049,385
-216,369
-17% -$3.9M 0.02% 491
2025
Q2 		$17.7M Buy
1,265,754
+17,033
+1% +$231K 0.02% 537
2025
Q1 		$16.8M Hold
1,248,721
– – 0.02% 538
2024
Q4 		$23.9M Buy
1,248,721
+223,384
+22% +$4.86M 0.03% 453
2024
Q3 		$23.3M Buy
1,025,337
+3,233
+0.3% +$52.9K 0.03% 450
2024
Q2 		$13.3M Sell
1,022,104
-73,337
-7% -$1.02M 0.02% 571
2024
Q1 		$19.2M Buy
1,095,441
+44,565
+4% +$864K 0.02% 502
2023
Q4 		$22.9M Sell
1,050,876
-15,467
-1% -$244K 0.03% 452
2023
Q3 		$16.4M Buy
+1,066,343
New +$20.3M 0.02% 510

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Pictet Asset Management's VRDN Position: Q2 2026 in Review

Pictet Asset Management reduced its Viridian Therapeutics (VRDN) stake by 96% in Q2 2026, selling an estimated $4.88M and leaving 11,225 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #1981.

Pictet Asset Management first reported a position in VRDN in Q3 2023 and has held it in 12 quarters since. The position peaked at $28.7M in Q4 2025. 70 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Pictet Asset Management held 11,225 shares of Viridian Therapeutics worth $206K as of Q2 2026.
  • Pictet Asset Management sold 302,806 Viridian Therapeutics shares in Q2 2026, an estimated $4.88M.
  • Viridian Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1981 holding.
  • Pictet Asset Management first reported a position in Viridian Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Viridian Therapeutics position peaked at $28.7M in Q4 2025.
  • 70 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.